Brief: Zealand Pharma Announces Positive Phase 2 Results For Petrelintide
05/03/2026 18:45
March 5 (Reuters) - Zealand Pharma A/S ZELA.CO: ZEALAND PHARMA ANNOUNCES POSITIVE PHASE 2 RESULTS FOR PETRELINTIDE, AN AMYLIN ANALOG WITH POTENTIAL TO REDEFINE THE WEIGHT MANAGEMENT EXPERIENCE FOR PEOPLE LIVING WITH OVERWEIGHT AND OBESITY ZEALAND PHARMA - PHASE 2 TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT WEIGHT REDUCTION AT 28 WEEKS ZEALAND PHARMA: NO UNEXPECTED SAFETY SIGNALS WERE OBSERVED WITH PETRELINTIDE TREATMENT Source text: ID:nGNX6swBBY Further company coverage: ZELA.CO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)